Emerging options for the treatment of melanoma – focus on ipilimumab

Emerging options for the treatment of melanoma – focus on ipilimumab

Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody. It has been approved by the US Food and Drug Administration (FDA) and the European Medici...

Full description

Bibliographic Details
Main Authors: Roddie C, Peggs KS
Format: Article
Language:English
Published: Dove Medical Press 2014-03-01
Series:ImmunoTargets and Therapy
Subjects:
Ipilimumab
cytotoxic T-lymphocyte antigen 4
advanced melanoma
metastatic
overall survival
Online Access:https://www.dovepress.com/emerging-options-for-the-treatment-of-melanoma-ndash-focus-on-ipilimum-peer-reviewed-article-ITT

Internet

https://www.dovepress.com/emerging-options-for-the-treatment-of-melanoma-ndash-focus-on-ipilimum-peer-reviewed-article-ITT

Similar Items